


## (3R,10R,14aS)-AZD4625

Cat. No.:	HY-146223A		
Molecular Formula:	C <sub>24</sub> H <sub>21</sub> ClF <sub>2</sub> N <sub>4</sub> O <sub>3</sub>		
Molecular Weight:	486.9		
Target:	Others		
Pathway:	Others		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (256.73 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	2.0538 mL	10.2690 mL	20.5381 mL
				5 mM	0.4108 mL	2.0538 mL	4.1076 mL
				10 mM	0.2054 mL	1.0269 mL	2.0538 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.27 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: 2.08 mg/mL (4.27 mM); Suspended solution; Need ultrasonic						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.08 mg/mL (4.27 mM); Clear solution; Need ultrasonic						

### BIOLOGICAL ACTIVITY

Description	(3R,10R,14aS)-AZD4625 is the isomer of AZD4625 (HY-146223), and can be used as an experimental control. AZD4625 (Compound 21) is a highly potent, selective, covalent and allosteric inhibitor of the mutant GTPase KRAS <sup>G12C</sup> . AZD4625 has high oral bioavailability <sup>[1]</sup> .
-------------	---

### REFERENCES

[1]. Kettle JG, et al. Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRAS<sup>G12C</sup>. J Med Chem. 2022 May 12;65(9):6940-6952.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA